ລາວເມດິແຄລ Laos Medicare,
#JACC Editors’ Insights: Mavacamten, a first-in-class reversible inhibitor of cardiac-specific myosin, was tested in patients…
#JACC Editors’ Insights: Mavacamten, a first-in-class reversible inhibitor of cardiac-specific myosin, was tested in patients…
#JACC Editors’ Insights: Mavacamten, a first-in-class reversible inhibitor of cardiac-specific myosin, was tested in patients…
#JACC Editors’ Insights: Mavacamten, a first-in-class reversible inhibitor of cardiac-specific myosin, was tested in patients…